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ORIGINAL ARTICLE
Probabilistic treatment planning for pancreatic cancer treatment: prospective
incorporation of respiratory motion shows only limited dosimetric benefit
Eelco Lensa, Alexis N. T. J. Kotteb, Ajay Patelb, Hanne D. Heerkensb, Matthieu Balc, Geertjan van Tienhovena,
Arjan Bela, Astrid van der Horsta and Gert J. Meijerb
aDepartment of Radiation Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; bDepartment of
Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands; cPhilips Healthcare, Eindhoven, The Netherlands
ABSTRACT
Background: We introduced a probabilistic treatment planning approach that prospectively incorpo-
rates respiratory-induced motion in the treatment plan optimization. The aim of this study was to
determine the potential dosimetric benefit by comparing this approach to the use of an internal target
volume (ITV).
Material and method: We retrospectively compared the probabilistic respiratory motion-incorporated
(RMI) approach to the ITV approach for 18 pancreatic cancer patients, for seven simulated respiratory
amplitudes from 5 to 50mm in the superior-inferior (SI) direction. For each plan, we assessed the target
coverage (required: D98%95% of 50Gy prescribed dose). For the RMI plans, we investigated whether tar-
get coverage was robust against daily variations in respiratory amplitude. We determined the distance
between the clinical target volume and the 30Gy isodose line (i.e. dose gradient steepness) in the SI dir-
ection. To investigate the clinical benefit of the RMI approach, we created for each patient an ITV and RMI
treatment plan for the three-dimensional (3D) respiratory amplitudes observed on their pretreatment 4D
computed tomography (4DCT). We determined Dmean, V30Gy, V40Gy and V50Gy for the duodenum.
Results: All treatment plans yielded good target coverage. The RMI plans were robust against respira-
tory amplitude variations up to 10mm, as D98% remained 95%. We observed steeper dose gradients
compared to the ITV approach, with a mean decrease from 25.9 to 19.2mm for a motion amplitude of
50mm. For the 4DCT motion amplitudes, the RMI approach resulted in a mean decrease of 0.43Gy,
1.1 cm3, 1.4 cm3 and 0.9 cm3 for the Dmean, V30Gy, V40Gy and V50Gy of the duodenum, respectively.
Conclusion: The probabilistic treatment planning approach yielded significantly steeper dose gradients
and therefore significantly lower dose to surrounding healthy tissues than the ITV approach. However,
the observed dosimetric gain for clinically observed respiratory motion amplitudes for this patient
group was limited.
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In pancreatic cancer treatment, pretreatment multi-modality
imaging enables for precise target definition and image-
guided radiation therapy allows for accurate positioning of
the patient. For example, by using daily cone beam com-
puted tomography (CBCT) scans together with intratumoral
fiducials, the uncertainties due to interfractional position var-
iations of the tumor can be reduced substantially [1,2]. An
important remaining uncertainty is the respiratory-induced
tumor motion [3].
Using an internal target volume (ITV) based on a single
four-dimensional (4D)CT measurement to account for the
respiratory motion is highly conservative and could lead to
unnecessary high doses to surrounding organs at risk (OARs)
[4]. Alternatively, gating or real-time tracking of the tumor
could be used. These procedures can yield good results, but
are also technically challenging and not possible on all treat-
ment machines [5,6].
Another approach would be to prospectively incorporate
the respiratory-induced tumor motion directly into the treat-
ment plan optimization process to achieve an optimal,
patient-specific solution given the respiratory motion. This
way the margins related to respiratory motion could be omit-
ted. To apply this method, an adaptation of the treatment
planning system as well as information about the expected
tumor motion is needed. Several groups have proposed such
adaptations to account for geometric uncertainties [7–13].
These methods mainly focused on systematic and interfrac-
tional uncertainties. In addition, all clinical data used to
evaluate the methods were for prostate cancer patients and
none showed the practicability for respiratory motion of
abdominal tumors. Jin et al. showed that delivering an
inhomogeneous dose distribution to lung tumors can result
in a steeper dose gradient around the target volume in the
presence of respiratory motion [14]. Inverse treatment
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planning while prospectively incorporating the respiratory
motion has been shown to be beneficial, but this has only
been demonstrated in a limited number of lung cancer
patients and only in a single liver cancer patient [15–17].
Therefore, clear evidence of the dosimetric benefit of using
probabilistic planning for gastrointestinal tumors is still lack-
ing. To determine the potential dosimetric benefit, probabilis-
tic planning should be systematically compared to a margin-
based approach for a larger patient cohort and a large range
of respiratory motion amplitudes. Also, before probabilistic
planning can be used in the clinic, its robustness against var-
iations in the respiratory motion must be investigated.
We developed a probabilistic treatment planning
approach that prospectively accounts for the respiratory-
induced motion of upper abdominal tumors in the optimiza-
tion process. This respiratory motion-incorporated (RMI)
approach was tested and compared to the ITV approach in a
group of pancreatic cancer patients using a wide range of
simulated and clinically observed motion amplitudes. The
goal of this study was to investigate whether the RMI
approach yielded clinically acceptable plans that were robust
against changes in respiratory motion amplitude. In addition,
we investigated the potential dosimetric benefit of the RMI
approach compared to the ITV approach.
Material and methods
Treatment plan optimization incorporating target
motion
A plugin was developed for the Pinnacle (version 9.710) treat-
ment planning software that incorporates respiratory-induced
tumor motion directly into the optimization process of the
inversely optimized treatment planning. The blurring of the
dose distribution with respect to the target volume as a result
of the respiratory-induced motion is taken into account when
determining the optimal dose distribution. This way, a static
dose distribution is calculated that when delivered to the
moving target, and thus convoluted with the respiratory
motion kernel, will result in that optimal dose distribution.
The used technique was similar to that described in previous
studies [7–13]. A detailed description of the implemented
algorithm is given in the Supplementary Material.
Patient cohort and treatment planning
To evaluate the developed RMI approach and compare it to
the ITV approach, we retrospectively studied a cohort of 18
patients who were diagnosed with resectable or borderline
resectable pancreatic cancer. All patients had 2–4 intratumoral
gold fiducial markers, had received a pretreatment 4DCT scan
and had tumor volumes ranging from 20 to 102 cm3 (mean
53 cm3). The tumor of patients 5, 11 and 18 was located in the
pancreatic body, body/tail and tail, respectively; all other
tumors were located in the pancreatic head.
All created treatment plans were inversely optimized
intensity-modulated radiotherapy (IMRT) plans using 10MV
photons with beams from seven gantry angles divided evenly
over a full 360 arc. For all plans, the prescription dose to
the planning target volume (PTV) was set to 50Gy. For the
RMI plans this PTV was the clinical target volume (CTV),
whereby the CTV comprised the gross tumor volume plus a 5-
mm margin for microscopic spread. The ITV was created by
expanding the CTV anisotropically using the corresponding
respiratory-induced motion amplitude [18]. In this study, both
the CTV-to-PTV and the ITV-to-PTV margin were set to 0mm
because we only considered the uncertainties due to respira-
tory motion. As a result, we directly used the ITV and the CTV
as the PTV for the ITV and RMI approach, respectively.
The following objectives were used for optimization: a
Dmax of 51Gy to the PTV [weight (w)¼ 10], Dmin of 50Gy to
the CTV (w¼ 10), and Dmax of 35Gy to a 15-mm thick shell
that was created at an isotropic distance of 6mm around the
PTV (w¼ 1).
Simulated motion amplitudes
First, we investigated the robustness of the RMI approach
against daily variations in tumor motion. Second, we system-
atically determined the potential dosimetric benefit of the
RMI approach compared to the ITV approach. Both the
robustness and dosimetric benefit were investigated using
treatment plans based on seven simulated respiratory motion
amplitudes up to 50mm. The seven respiratory motion
amplitudes (A¼ 5, 10, 15, 20, 30, 40 and 50mm) were used
to create both ITV and RMI plans for each patient; this
resulted in 14 treatment plans per patient, 252 plans in total.
We only included the respiratory motion in the superior-infer-
ior (SI) direction and the probability density functions (PDFs)
describing the different motion amplitudes were based on a
single motion trace (Figure 1). This way, the comparison
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Figure 1. The motion trace describing the respiratory-induced tumor motion in
inferior-superior direction for the 10 respiratory phases, as used for the simu-
lated amplitudes. The motion trace is normalized to yield a peak-to-peak ampli-
tude of 1; phase 1: end-inhale, phase 6: end-exhale.
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between the ITV and RMI approach could be made solely as
a function of the respiratory motion amplitude. Also, we
expected the greatest effect to be in the SI direction because
here the dose gradient was steepest due to the planar irradi-
ation technique that was used. We used the motion trace
that described the respiratory-induced tumor motion in the
SI direction of patient 10. This motion trace described the
tumor motion as typically observed in the clinic on the 10
phase scans of a 4DCT (i.e. a smooth continuous curve with
the average tumor position in phase 2 and the exhale pos-
ition in phase 6). The PDFs describing the different motion
amplitudes were obtained by scaling the motion trace to
simulate different peak-to-peak amplitudes. The probability
of each tumor position was 0.1 and the tumor position in
the respiratory phase that contains the tumor in its position
closest to the mean position (i.e. tumor position in phase 2)
was set to zero. To simulate the delivery of the treatment
plan to a moving target (e.g. pancreatic tumor during free
breathing) all dose distributions were convolved with the
PDF that was also used for the treatment plan optimization,
in order to obtain the final dose distributions [19].
To determine whether the RMI approach yielded clinically
acceptable plans, we determined for each plan whether tar-
get coverage was obtained, with target coverage defined as
D98%95% (i.e. the dose to 98% of the CTV should be at
least 47.5 Gy).
The observed respiratory motion amplitude can vary sub-
stantially between what was observed at treatment planning
and what was observed during daily treatment [3]. In an ear-
lier study we observed that during 17% out of a total of 401
treatment fractions the motion amplitude differed5mm
compared to what was observed during treatment planning
[3]. We investigated the extent to which the RMI plans were
robust in terms of target coverage against the daily varia-
tions in tumor motion. We analyzed the effect on the target
coverage of applying a different respiratory motion ampli-
tude for the convolution of the optimized dose distribution
(i.e. treatment delivery simulation) than was used for treat-
ment plan optimization. As we used a single motion trace to
describe tumor motion, and the main difference between
patients was the tumor size, we demonstrated the robustness
for the smallest (patient 12) and largest tumor (patient 17),
only. For both patients, each of the seven dose distributions,
optimized for a specific respiratory motion amplitude ranging
from 5 to 50mm, was convolved with eight PDFs (corre-
sponding to amplitudes ranging from 0 to 50mm), resulting
in 56 different combinations per patient. For each combin-
ation, D98% of the CTV was determined. We did not investi-
gate the robustness against variations in the motion
amplitude in all three directions as we expected the largest
variations in the SI direction [3]. Also, because the dose gra-
dient was steepest in the SI direction, variations in respiratory
amplitudes in that direction will have the greatest effect on
target coverage.
We systematically determined the difference in dose gradi-
ent steepness in the SI direction of the RMI approach com-
pared to the ITV approach for respiratory motion amplitudes
of up to 50mm. We obtained the maximum distance in the
inferior direction between the CTV and the 30Gy isodose line
was determined in the coronal CT slice that contained the
isocenter of the treatment plan and used as a measure for
dose gradient steepness. This distance was chosen as a
measure for gradient steepness because it also gave informa-
tion on whether the high-dose volumes conformed to the
CTV, whereas the distance between two isodose lines, which
is often used to describe the dose gradient, does not. For
each analyzed respiratory motion amplitude, the average and
standard deviation of the steepness over all patients were
determined and plotted, for ITV and RMI separately. For each
motion amplitude, the statistical significance of the difference
of the dose gradient steepness between the RMI and the ITV
approach was tested using the Wilcoxon signed-rank test.
To illustrate the potential dosimetric benefit of using the
RMI approach for the surrounding OARs, we analyzed the
Dmean, V30Gy, V40Gy and V50Gy of the duodenum for all ITV
and RMI plans for patients 12 and 17 (i.e. smallest and largest
tumor, respectively). We determined the differences in the
four dosimetric parameters of the duodenum between the
RMI and ITV approach for all simulated respiratory-induced
motion amplitudes. The Wilcoxon signed-rank test was used
to test whether these differences were statistically significant.
Clinically observed three-dimensional motion
amplitudes
To determine the benefit of the RMI approach compared to
the ITV approach in a more clinical setting, we also created
treatment plans using clinically observed respiratory motion
amplitudes. Two treatment plans were made for each patient
that were based on the 3D [i.e. SI, anterior-posterior (AP) and
left-right (LR)] respiratory-induced motion as was observed
on the clinically used pretreatment 4DCT scan; one using the
ITV approach and one using the RMI approach. Again, all
dose distributions were convolved with the PDF that was
also used for the treatment plan optimization, to simulate
the respiratory motion during treatment delivery [19].
To investigate the dosimetric benefit of the RMI approach
for clinically observed respiratory motion amplitudes com-
pared to the ITV approach, we determined the difference in
dose to the duodenum. The duodenum was the OAR that
was positioned closest to the PTV and for which the dose
was expected to be influenced the most by a difference in
dose gradient around the PTV. The Dmean, V30Gy, V40Gy and
V50Gy of the duodenum were analyzed for all ITV and RMI
plans. The Wilcoxon signed-rank test was used to test
whether these differences were statistically significant and
Bland-Altman plots were created to visualize the differences.
Results
Simulated motion amplitudes
All RMI plans had good target coverage (D98%>95%) when
the dose distribution was convolved with the same PDF as
was used for the optimization procedure. Supplementary
Figures B1(a–f) and B2(a–f) show, for patients 12 and 17,
three examples of RMI dose distributions, for respiratory
motion amplitudes of 5, 20 and 50mm in the SI direction.
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The static dose distributions (before convolution) can be
highly inhomogeneous and the regions receiving high dose
can extend to outside the target volume. After convolution,
the distributions were homogeneous and conform to the
CTV. For the ITV plans, the dose distributions were more con-
form to the CTV (Supplementary Figures B1(g–l) and B2(g–l))
after convolution.
The target coverage of the RMI plans was robust when
the anticipated respiratory motion amplitude was 20mm
and the amplitude during treatment delivery was either
10mm smaller or 5mm larger (Figure 2). This was within
the range of clinically expected amplitude variations.
The use of the RMI approach resulted in significantly
(p .0002) steeper dose gradients for each simulated motion
amplitude compared to the use of the ITV approach
(Figure 3). A difference in the dose gradient of 1.7mm
(respiratory motion amplitude of 5mm) up to 6.7mm (ampli-
tude of 50mm) was observed. Both approaches show a
strong linear relationship (R2 .995) between the respiratory
motion amplitude and the steepness of the dose gradient.
The small standard deviations in the distance over all 18
patients (error bars, Figure 3) indicate there is little effect of
tumor volume on the steepness of the dose gradient around
the CTV.
Table 1 shows the results for the evaluated dosimetric
parameters of the duodenum for patients 12 and 17, for
both the ITV and the RMI approach when using the simu-
lated respiratory amplitudes. All parameters decreased
significantly (p .016), up to 51% for the V50Gy of patient 17
for a respiratory amplitude of 50mm, when using the RMI
instead of the ITV approach.
Clinically observed three-dimensional motion
amplitudes
The mean respiratory-induced motion amplitudes that were
measured on the 4DCT and used to determine the clinical
benefit were 2.4 (standard deviation 1.1; range 0.6–4.6) mm,
3.0 (1.0; 1.2–5.0) mm and 8.8 (3.3; 4.0–16.2) mm in LR, AP
and SI, respectively. When applying these clinically observed
respiratory motion amplitudes, the analyzed Dmean, V30Gy,
V40Gy and V50Gy parameters for the duodenum decreased by
0.43 Gy, 1.1 cm3, 1.4 cm3 and 0.9 cm3, respectively (Figure 4).
All differences, although statistically significant (p .009),
were small and therefore not expected to have a high clinical
impact.
Discussion
The developed treatment planning approach prospectively
incorporated respiratory motion of pancreatic tumors in the
optimization of the treatment planning process and gener-
ated treatment plans that were directly deliverable by a
treatment machine. The created treatment plans resulted in
inhomogeneous dose distributions when delivered to a static
target. To simulate respiratory motion during treatment deliv-
ery, the dose distributions were convolved with the expected
tumor motion. After convolution, these RMI plans yielded
good target coverage, steeper dose gradients and therefore
significantly lower dose to surrounding OARs when com-
pared to the use of an ITV. This is in agreement with earlier
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Figure 2. D98% for the CTV as a function of the motion amplitude during treat-
ment delivery simulation, for patient 12 (smallest tumor) and patient 17 (largest
tumor), showing the robustness of the RMI treatment plans against daily varia-
tions in breathing amplitudes. For example, the solid blue lines represent D98%
for various breathing amplitudes for a plan that was optimized for a 5-mm
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ACTA ONCOLOGICA 401
D
ow
nl
oa
de
d 
by
 [R
ad
bo
ud
 U
niv
ers
ite
it N
ijm
eg
en
] a
t 0
4:2
9 0
2 O
cto
be
r 2
01
7 
results from the literature where the inferiority of the ITV was
shown for a lung and a liver case [15]. However, for clinically
observed respiratory-induced motion amplitudes, the differ-
ences in dose to the duodenum, which was in close proxim-
ity to the PTV and expected to be affected most by a change
in the dose gradient, were small.
An earlier study showed that in clinical practice, 4DCT
overestimates the respiratory-induced motion amplitude
compared to the daily tumor motion for the majority of
patients [3]. This overestimate was typically in the range of
5–10mm, with the amplitudes in the SI direction on 4DCT
typically 20mm. The current study shows that the RMI
Table 1. Dosimetric parameters for the duodenum for patients 12 and 17, for both the ITV and RMI approach (7 respiratory motion amplitudes each).
ITV RMI
A (mm) Dmean (Gy) V30Gy (cm
3) V40Gy (cm
3) V50Gy (cm
3) Dmean (Gy) V30Gy (cm
3) V40Gy (cm
3) V50Gy (cm
3)
Patient 12 5 34.1 55.5 35.9 11.4 32.9 52.9 32.7 9.4
10 35.6 58.7 38.8 12.8 33.6 53.9 33.1 10.2
15 36.9 61.7 41.1 14.2 33.9 54.2 33.2 9.9
20 38.0 64.3 43.1 14.7 35.8 59.8 36.5 8.9
30 39.6 68.4 46.1 15.4 36.2 60.2 35.9 8.8
40 40.7 72.5 48.7 15.7 38.2 67.5 40.0 8.1
50 41.2 74.5 49.8 16.3 38.0 66.5 37.3 8.4
Patient 17 5 42.4 87.9 69.4 35.5 40.9 83.0 63.7 31.0
10 43.6 92.1 74.3 35.7 41.3 83.7 65.0 31.5
15 44.8 96.8 78.9 39.9 41.8 86.6 65.9 30.9
20 45.4 99.7 82.1 38.9 42.2 89.4 67.0 28.7
30 46.2 101.8 87.2 40.7 43.1 94.6 70.3 27.8
40 46.6 102.3 90.3 39.7 43.5 97.5 71.8 26.5
50 46.8 102.5 92.2 40.8 43.5 99.9 71.8 20.0
A: respiratory motion amplitude; ITV: internal target volume; Pat: patient; RMI: respiratory motion-incorporated.
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Figure 4. Bland-Altman plots for the duodenum, showing for each dosimetric parameter the difference (i.e. ITV value minus RMI value) for all 18 patients. The clin-
ically observed three-dimensional motion amplitudes were used.
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approach yielded clinically acceptable plans for moving tar-
gets that had a motion amplitude of up to 50mm in the SI
direction. In a clinical setting this approach would result in
treatment plans that are robust in terms of target coverage
against expected variations in respiratory amplitude,
although the dose inhomogeneity might increase (Figure 5).
The ITV approach, inherently, will always yield sufficient tar-
get coverage and a homogeneous dose distribution when
the motion amplitude during treatment is smaller than the
amplitude used to create the ITV.
This study only considered rigid motion patterns, which
limited the ability to accurately determine the benefit of
using a probabilistic treatment planning approach for radio-
therapy of pancreatic cancer. The developed approach can
be extended to include anatomical deformations as well.
However, the effects of deformations are expected to be
minimal as it has been shown that the dosimetric differences,
for both the target volume and healthy tissues, between
using deformable image registration compared to rigid body
translations are small in the upper abdominal region [20].
The interplay effect between treatment delivery over time
and tumor motion was neglected as this does not affect the
delivered dose [21].
The RMI approach resulted in a significant reduction of
dose to the duodenum when compared to the ITV approach.
High-dose volumes (V55Gy>1 cm
3 and V50Gy>16 cm
3) of the
duodenum have been identified as strong predictors for tox-
icity [22,23]. The steeper dose gradient obtained by the RMI
approach reduces these high-dose volumes, as was shown in
this study. As the duodenum overlapped with the PTV for
all patients, using the maximum dose as an evaluation
parameter was not suitable to evaluate the difference
between the ITV and RMI approach.
In an earlier study we showed that the use of a mid-venti-
lation approach for irradiation of pancreatic tumors can sig-
nificantly reduce the dose to surrounding OARs while
maintaining sufficient target coverage [18]. However, in the
RMI approach the treatment planning system has the add-
itional freedom to create initially inhomogeneous dose distri-
butions, which can result in steep dose gradients in the final
convolved dose distribution. The mid-ventilation approach
merely applies smaller margins than the ITV approach and
thus creates a homogeneous dose distribution. However,
because in this study we compared the RMI approach to the
ITV (a highly conservative technique) and we only observed
minimal dosimetric gain, we expect the dosimetric difference
between the mid-ventilation and RMI approach to be
small. Further research is needed to determine which tech-
nique might be better in terms of robustness against varia-
tions in the respiratory amplitude and reducing the dose
to OARs.
RMI planning and treatment requires accurate alignment
of the mean tumor position during treatment with the
expected mean tumor position from the planning CT scan.
As a result of the more conformal dose distributions com-
pared to the use of an ITV, the dosimetric impact of a mis-
match might be larger for the RMI approach. It is therefore
recommended to daily position the patient by registration of
the mean tumor position obtained from a daily 4D-CBCT
with the mean tumor position during respiration obtained
from a pretreatment 4DCT combined with the use of intratu-
moral fiducials. For this daily position verification, small
(i.e. ø¼ 0.28–0.35mm) intratumoral fiducials that can be
Figure 5. For patients 12 (top) and 17 (bottom), dose distribution optimized for a simulated respiratory amplitude of 20mm using the RMI approach (a and c) and
the same distributions convolved with the PDF describing a simulated respiratory motion amplitude of 10mm (b and d).
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implanted during a endoscopic procedure can be used
[1,2,24].
Our results show that our newly developed approach of
prospectively incorporating respiratory-induced pancreatic
tumor motion in the optimization process can yield more
conformal dose distributions compared to the ITV approach.
However, the dosimetric gain highly depends on the
respiratory-induced motion amplitude; for the 18 patients for
whom treatment plans were based on the clinical ampli-
tudes, we observed only small differences in dose to the
duodenum. When the respiratory motion amplitude becomes
larger (i.e.>15mm) the dosimetric benefit becomes more
substantial. In daily clinical practice, treatment planning com-
bined with probabilistic optimization will likely result in only
a minimal clinical gain and for each treatment site it should
be determined what this gain on average would be. For pan-
creatic cancer patients, we recommend using a probabilistic
planning strategy only when the respiratory-induced motion
amplitude is >15mm, which might occur in only a limited
number of patients. For smaller amplitudes using a simple
expansion of the target volume to account for the respiratory
motion may be sufficient.
In conclusion, prospective incorporation of respiratory-
induced pancreatic tumor motion in the treatment plan opti-
mization process resulted in treatment plans that had good
target coverage and were robust against variations in the
respiratory motion amplitude within a certain bandwidth.
Probabilistic treatment plans had significantly steeper dose
gradients and therefore yielded significantly lower dose to
surrounding OARs compared to the use of an ITV. However,
the potential clinical gain of this treatment planning tech-
nique for this patient group was limited.
Disclosure statement
Dr Bal works for Philips. Dr Bel does consultancy work for Elekta, is pro-
ject leader of several Elekta-sponsored projects and reports non-financial
support from Raysearch outside of this work. Philips, Elekta and
Raysearch had no involvement in study design, data collection and ana-
lysis, or writing of the manuscript.
Funding
This work was supported by the foundation Bergh in het Zadel through
the Dutch Cancer Society (KWF Kankerbestrijding) project no. UVA 2011-
5271.
References
[1] van der Horst A, Wognum S, Davila Fajardo R, et al. Interfractional
position variation of pancreatic tumors quantified using intratu-
moral fiducial markers and daily cone beam computed tomog-
raphy. Int J Radiat Oncol Biol Phys. 2013;87:202–208.
[2] van der Horst A, Lens E, Wognum S, et al. Limited role for biliary
stent as surrogate fiducial marker in pancreatic cancer: stent and
intratumoral fiducials compared. Int J Radiat Oncol Biol Phys.
2014;89:641–648.
[3] Lens E, van der Horst A, Kroon PS, et al. Differences in respira-
tory-induced pancreatic tumor motion between 4D treatment
planning CT and daily cone beam CT, measured using intratu-
moral fiducials. Acta Oncol. 2014;53:1257–1264.
[4] Mutaf YD, Brinkmann DH. Optimization of internal margin to
account for dosimetric effects of respiratory motion. Int J Radiat
Oncol Biol Phys. 2008;70:1561–1570.
[5] Verellen D, Depuydt T, Gevaert T, et al. Gating and tracking, 4D
in thoracic tumours. Cancer Radiother. 2010;14:446–454.
[6] Heerkens HD, van Vulpen M, van den Berg CAT, et al. MRI-based
tumor motion characterization and gating schemes for radiation
therapy of pancreatic cancer. Radiother Oncol. 2014;111:252–257.
[7] Li JG, Xing L. Inverse planning incorporating organ motion. Med
Phys. 2000;27:1573–1578.
[8] Birkner M, Yan D, Alber M, et al. Adapting inverse planning to
patient and organ geometrical variation: algorithm and imple-
mentation. Med Phys. 2003;30:2822–2831.
[9] Unkelbach J, Oelfke U. Inclusion of organ movements in IMRT
treatment planning via inverse planning based on probability dis-
tributions. Phys Med Biol. 2004;49:4005–4029.
[10] Chan TCY, Bortfeld T, Tsitsiklis JN. A robust approach to IMRT
optimization. Phys Med Biol. 2006;51:2567–2583.
[11] Moore JA, Gordon JJ, Anscher MS, et al. Comparisons of treat-
ment optimization directly incorporating random patient setup
uncertainty with a margin-based approach. Med Phys.
2009;36:3880–3890.
[12] Moore JA, Gordon JJ, Anscher MS, et al. Comparisons of treat-
ment optimization directly incorporating systematic patient setup
uncertainty with a margin-based approach. Med Phys.
2012;39:1102–1111.
[13] Bohoslavsky R, Witte MG, Janssen TM, et al. Probabilistic objective
functions for margin-less IMRT planning. Phys Med Biol.
2013;58:3563–3580.
[14] Jin J-Y, Ajlouni M, Kong F-MS, et al. Utilize target motion to cover
clinical target volume (ctv)–a novel and practical treatment plan-
ning approach to manage respiratory motion. Radiother Oncol.
2008;89:292–303.
[15] Trofimov A, Rietzel E, Lu H-M, et al. Temporo-spatial IMRT opti-
mization: concepts, implementation and initial results. Phys Med
Biol. 2005;50:2779–2798.
[16] S€ohn M, Weinmann M, Alber M. Intensity-modulated radiotherapy
optimization in a quasi-periodically deforming patient model. Int.
J Radiat Oncol Biol Phys. 2009;75:906–914.
[17] Heath E, Unkelbach J, Oelfke U. Incorporating uncertainties in
respiratory motion into 4D treatment plan optimization. Med
Phys. 2009;36:3059–3071.
[18] Lens E, van der Horst A, Versteijne E, et al. Dosimetric advantages
of midventilation compared with internal target volume for radi-
ation therapy of pancreatic cancer. Int J Radiat Oncol Biol Phys.
2015;92:675–682.
[19] Bel A, van Herk M, Lebesque JV. Target margins for random geo-
metrical treatment uncertainties in conformal radiotherapy. Med
Phys. 1996;23:1537–1545.
[20] Velec M, Moseley JL, Eccles CL, et al. Effect of breathing motion
on radiotherapy dose accumulation in the abdomen using
deformable registration. Int J Radiat Oncol Biol Phys.
2011;80:265–272.
[21] Bortfeld T, Jokivarsi K, Goitein M, et al. Effects of intra-fraction
motion on IMRT dose delivery: statistical analysis and simulation.
Phys Med Biol. 2002;47:2203–2220.
[22] Nakamura A, Shibuya K, Matsuo Y, et al. Analysis of dosimetric
parameters associated with acute gastrointestinal toxicity and
upper gastrointestinal bleeding in locally advanced pancreatic
cancer patients treated with gemcitabine-based concurrent che-
moradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84:369–375.
[23] Kelly P, Das P, Pinnix CC, et al. Duodenal toxicity after fractio-
nated chemoradiation for unresectable pancreatic cancer. Int J
Radiat Oncol Biol Phys. 2013;85:e143–e149.
[24] Davila Fajardo R, Lekkerkerker SJ, van der Horst A, et al. EUS-
guided fiducial markers placement with a 22-gauge needle for
image-guided radiation therapy in pancreatic cancer. Gastrointest
Endosc. 2014;79:851.
404 E. LENS ET AL.
D
ow
nl
oa
de
d 
by
 [R
ad
bo
ud
 U
niv
ers
ite
it N
ijm
eg
en
] a
t 0
4:2
9 0
2 O
cto
be
r 2
01
7 
